the evaluation of PAH severity is based on the examination of many parameters simultaneously. The purpose of the study is to find out whether serum NTpro-BNP and uric acid could be the reliable noninvasive parameters for pulmonary arterial hypertension (PAH) severity assessment in patients (pts) with pulmonary arterial hypertension.Material and methods
26 pts (19F/7M, 43.2 ± 14.3 years):11 idiopathic PAH (IPAH) pts, 5 pts -PAH associated with corrected congenital heart disease (CHD), 8 chronic thromboembolic pulmonary hypertension (CTEPH) pts, 2 pts with scleroderma. 6MWT, right heart catheterization (RHC), serum NTpro-BNP and uric acid concentrations were carried out.Results
38.5% pts had symptoms of II FC NYHA, 46% pts-class III and 15.5%-class IV. 6MWT was decreased 343.7 ± 136 m. Increased Nt-proBNP and uric acid levels were associated with decreased 6MWT (r=-0.65, p < 0.01; r=- 0.46, p < 0.01 respectively). Negative correlation was determined between uric acid content and oxygen saturation at the end of 6MWT (r=-0.58, p < 0.01). There was negative correlation between NT-proBNP level and systolic arterial pressure (SAP) (r=-0.44, p=0.03), cardiac index (CI) (r=-0.57, p < 0.01), mixed venous oxygen saturation (SvO2) and positive correlation with mean right atrial pressure (RAPm) (r=0.41, p=0.04), pulmonary vascular resistance index (PVRI) (r=0.66, p < 0.01). Positive correlation was revealed between uric acid and RAPm (r=0.48, p=0.03), and negative correlation was observed with CI (r=-0.36, p=0.03) and SvO2 (r=-0.46, p=0.03).Conclusion
serum NT-proBNP and uric acid are the suitable markers for noninvasive follow-up patients with PAH due to their high correlations with hemodinamic and functional parameters.